Fleur M van der Valk1, Carlijn Kuijk2, Simone L Verweij1, Lotte C A Stiekema1, Y Kaiser1, Sacha Zeerleder3,4, Matthias Nahrendorf5, Carlijn Voermans2, Erik S G Stroes1. 1. Department of Vascular Medicine, AMC, Room F4-146, PO Box 22660, 1100 DD, Amsterdam, The Netherlands. 2. Department of Hematopoiesis, Sanquin Research, and Landsteiner Laboratory, Academic Medical Centre, University of Amsterdam, Amsterdam, The Netherlands. 3. Department of Hematology, AMC, Amsterdam, The Netherlands. 4. Department of Immunopathology, Sanquin Research, Amsterdam, The Netherlands. 5. Center for Systems Biology, Massachusetts General Hospital and Harvard Medical School, Boston, USA.
Abstract
Aims: Experimental work posits that acute ischaemic events trigger haematopoietic activity, driving monocytosis, and atherogenesis. Considering the chronic low-grade inflammatory state in atherosclerosis, we hypothesized that haematopoietic hyperactivity is a persistent feature in cardiovascular disease (CVD). Therefore, we aimed to assess the activity of haematopoietic organs and haematopoietic stem and progenitor cells (HSPCs) in humans. Methods and results: First, we performed 18F-fluorodeoxyglucose positron emission tomographic (18F-FDG PET) imaging in 26 patients with stable atherosclerotic CVD (ischaemic event >12 months ago), and 25 matched controls. In splenic tissue, 18F-FDG uptake was 2.68 ± 0.65 in CVD patients vs. 1.75 ± 0.54 in controls (1.6-fold higher; P< 0.001), and in bone marrow 3.20 ± 0.76 vs. 2.72 ± 0.46 (1.2-fold higher; P = 0.003), closely related to LDL cholesterol levels (LDLc, r = 0.72). Subsequently, we determined progenitor potential of HSPCs harvested from 18 patients with known atherosclerotic CVD and 30 matched controls; both groups were selected from a cohort of cancer patients undergoing autologous stem cell transplantation. In CVD patients, the normalized progenitor potential, expressed as the number of colony-forming units-granulocyte/monocyte (CFU-GM) colonies/CD34+ cell, was 1.6-fold higher compared with matched controls (P < 0.001). Finally, we assessed the effects of native and oxidized lipoproteins on HSPCs harvested from healthy donors in vitro. Haematopoietic stem and progenitor cells displayed a 1.5-fold increased CFU-GM capacity in co-culture with oxidized LDL in vitro (P = 0.002), which was inhibited by blocking oxidized phospholipids via E06 (P = 0.001). Conclusion: Collectively, these findings strengthen the case for a chronically affected haematopoietic system, potentially driving the low-grade inflammatory state in patients with atherosclerosis. Published on behalf of the European Society of Cardiology. All rights reserved.
Aims: Experimental work posits that acute ischaemic events trigger haematopoietic activity, driving monocytosis, and atherogenesis. Considering the chronic low-grade inflammatory state in atherosclerosis, we hypothesized that haematopoietic hyperactivity is a persistent feature in cardiovascular disease (CVD). Therefore, we aimed to assess the activity of haematopoietic organs and haematopoietic stem and progenitor cells (HSPCs) in humans. Methods and results: First, we performed 18F-fluorodeoxyglucose positron emission tomographic (18F-FDG PET) imaging in 26 patients with stable atherosclerotic CVD (ischaemic event >12 months ago), and 25 matched controls. In splenic tissue, 18F-FDG uptake was 2.68 ± 0.65 in CVD patients vs. 1.75 ± 0.54 in controls (1.6-fold higher; P< 0.001), and in bone marrow 3.20 ± 0.76 vs. 2.72 ± 0.46 (1.2-fold higher; P = 0.003), closely related to LDL cholesterol levels (LDLc, r = 0.72). Subsequently, we determined progenitor potential of HSPCs harvested from 18 patients with known atherosclerotic CVD and 30 matched controls; both groups were selected from a cohort of cancerpatients undergoing autologous stem cell transplantation. In CVD patients, the normalized progenitor potential, expressed as the number of colony-forming units-granulocyte/monocyte (CFU-GM) colonies/CD34+ cell, was 1.6-fold higher compared with matched controls (P < 0.001). Finally, we assessed the effects of native and oxidized lipoproteins on HSPCs harvested from healthy donors in vitro. Haematopoietic stem and progenitor cells displayed a 1.5-fold increased CFU-GM capacity in co-culture with oxidized LDL in vitro (P = 0.002), which was inhibited by blocking oxidized phospholipids via E06 (P = 0.001). Conclusion: Collectively, these findings strengthen the case for a chronically affected haematopoietic system, potentially driving the low-grade inflammatory state in patients with atherosclerosis. Published on behalf of the European Society of Cardiology. All rights reserved.
Authors: Ryu Watanabe; Marc Hilhorst; Hui Zhang; Markus Zeisbrich; Gerald J Berry; Barbara B Wallis; David G Harrison; John C Giacomini; Jörg J Goronzy; Cornelia M Weyand Journal: JCI Insight Date: 2018-10-18
Authors: Zahi A Fayad; Filip K Swirski; Claudia Calcagno; Clinton S Robbins; Willem Mulder; Jason C Kovacic Journal: J Am Coll Cardiol Date: 2018-10-30 Impact factor: 24.094
Authors: Alexander Heyde; David Rohde; Cameron S McAlpine; Shuang Zhang; Friedrich F Hoyer; Jeffrey M Gerold; David Cheek; Yoshiko Iwamoto; Maximilian J Schloss; Katrien Vandoorne; Oriol Iborra-Egea; Christian Muñoz-Guijosa; Antoni Bayes-Genis; Johannes G Reiter; Morgan Craig; Filip K Swirski; Matthias Nahrendorf; Martin A Nowak; Kamila Naxerova Journal: Cell Date: 2021-02-25 Impact factor: 66.850
Authors: Kikkie Poels; Suzanne I M Neppelenbroek; Marie José Kersten; M Louisa Antoni; Esther Lutgens; Tom T P Seijkens Journal: J Immunother Cancer Date: 2021-06 Impact factor: 13.751